Tag: MM


FDA Grants Orphan Drug Designation to BCMA-Targeted TriTAC HPN217 for Myeloma

  Jan 13 2021 Tagged MM, anti-BCMA

The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct (TriTAC) as treatment for patients with multiple myeloma, according to an announcement from Harpoon Therapeutics, Inc.

Visit website
Immunotherapy Web Featured Images 26

The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Pati...

  Nov 11 2020 Tagged mAbs, MM

This is the first monoclonal antibody to target this antigen in multiple myeloma, which represents a true novelty from a pharmacological point of view.

Visit website